|
Canada-0-Financing Azienda Directories
|
Azienda News:
- Drug Approvals and Databases | FDA
Downloadable data files FDA Adverse Event Reporting System (FAERS) Public Dashboard Inactive Ingredient Search for Approved Drug Products Search More information Medication Guides Search More
- Novel Drug Approvals for 2025 | FDA
FDA Novel Drug Therapy Approvals for 2025 In 2025, CDER approved 46 new drugs never before approved or marketed in the U S , known as “novel” drugs
- FDA-Approved Treatments for Alzheimers
FDA-Approved Drugs For Alzheimer's The FDA has approved medications that fall into two categories: drugs that change disease progression in people living with early Alzheimer's disease, and drugs that may temporarily mitigate some symptoms of Alzheimer's dementia
- New FDA Drug Approvals for 2026 - Drugs. com
Up to date information on the latest FDA drug approvals Includes list of most recent approvals, the conditions approved for, and the approval history
- FDA approves Denali Hunter syndrome drug - fiercepharma. com
The FDA has approved Denali Therapeutics’ enzyme replacement therapy for a genetic lysosomal storage disease after a string of high-profile rejections for rare disease candidates In approving
- This rare disease destroys a childs ability to walk and . . .
After a string of denials for rare disease treatment candidates, the FDA last week greenlit a drug for Hunter syndrome, a progressive illness affecting about 500 Americans
- WTAS: FDA Approves Drug to Treat Neurologic Manifestations of . . .
Media round-up on FDA’s approval of Avlayah to treat certain individuals with Hunter syndrome
- UPLIZNA® (INEBILIZUMAB-CDON) IS NOW THE FIRST AND ONLY FDA . . .
"The FDA approval of UPLIZNA marks a significant turning point for IgG4-RD patients and physicians who now have a proven treatment that targets a key driver of the disease, reducing the risk of flares and reliance on harmful long-term steroid use," said Jay Bradner, M D , executive vice president of Research and Development at Amgen
- FDA ties Amgen’s rare inflammatory disease drug to eight . . .
The FDA in January asked Amgen to pull Tavneos from the market, citing liver toxicity issues that affected the drug’s overall risk-benefit profile The pharma refused
- FDA Approves Ozempic For Type 2 Diabetes and Chronic Kidney . . .
On January 28, 2025, the U S Food and Drug Administration (FDA) approved Ozempic for use in people with type 2 diabetes and kidney disease This approval marks an important milestone in kidney disease treatment, offering a new option to help reduce complications like heart disease, dialysis, or kidney transplant
|
|